Market Closed - Euronext Paris 11:36:58 2024-04-19 am EDT 5-day change 1st Jan Change
33.8 EUR +2.27% Intraday chart for Guerbet +0.90% +73.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Guerbet: CE certificate for a platform CF
Intrasense: awarded CE certificate CF
Guerbet SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Guerbet: results exceed expectations, share price rises CF
Guerbet: two appointments to the executive committee CF
CAC40: gloomy end to the week, timid weekly gain (+0.7%) CF
Guerbet: sales growth of 4% by 2023 CF
Guerbet SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guerbet SA(ENXTPA:GBT) dropped from S&P Global BMI Index CI
Guerbet SA completed the acquisition of 17.82% stake in Intrasense SA. CI
Global markets live: Boeing, Google, Meta, Sonos... Our Logo
Guerbet Announces Management Appointments CI
Applied Radiology and Guerbet Launch 'Elucirem (Gadopiclenol) Injection CI
Guerbet SA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Guerbet SA Provides Revenue Guidance for the Second Half and Full Year 2023 CI
Guerbet SA launched a takeover bid to acquire remaining 61.32% stake in Intrasense SA for ?14 million. CI
Guerbet Releases First Production Batch of Elucirem (Gadopiclenol) Injection, a Novel New Macrocyclic GBCA for Use in Contrast-Enhanced Magnetic Resonance Imaging CI
Guerbet to Launch Voluntary Tender Offer for Intrasense After Acquiring 39% Stake MT
Intrasense SA announced that it has received €8.8 million in funding from Guerbet SA CI
Guerbet SA Revises Group Earnings Guidance for the Year 2022 CI
Guerbet SA Reports Earnings Results for the Half Year Ended June 30, 2022 CI
France's Guerbet Wins Public Grant To Develop Technology For Early Detection Of Pancreatic Cancer MT
Guerbet's Contrast-enhanced MRI Agent Elucirem Wins US FDA Nod MT
Guerbet Announces U.S. Food and Drug Administration Approval of Elucirem (Gadopiclenol) CI
Guerbet SA(ENXTPA:GBT) added to S&P Global BMI Index CI
Chart Guerbet
More charts
Guerbet is a European leader in producing and selling contrast products for medical imaging. The group's products make it possible to visualize different organs and the lymphatic and vascular systems of the human body by making them opaque. Net sales break down by product family as follows: - X-ray imaging products (55.4%); - MRI products (32.7%); - other (11.9%): contrast products for echography and nuclear medicine, fine chemicals products. At the end of 2023 the group had 8 production sites located in France (4), the United States (2), Ireland and Brazil. Europe accounts for 39.7% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
33.05 EUR
Average target price
38.63 EUR
Spread / Average Target
+16.89%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. GBT Stock
  4. News Guerbet
  5. Guerbet S A : Injects Nearly $4 Million in NH TherAguix's IPO in Paris